Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease
Status:
Not yet recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, randomized, double-blind, multicenter study to assess the therapeutic
efficacy, safety, and mechanisms of omilancor (BT-11) in patients with moderate to severe
Crohn's Disease (CD). The purpose of this study is to evaluate target engagement and the
mechanism of action of BT-11 compared to adalimumab in subjects with moderately to severely
active CD.